Navigation Links
Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
Date:6/25/2008

proteins encoded by the polynucleotides. Vical's patent coverage includes delivery of linear DNA as well as plasmid DNA.

Currently plasmid DNA vaccines, which are under development against pandemic influenza and other infectious diseases at Vical, are manufactured by bacterial fermentation in standardized equipment with a production time measured in weeks rather than months. While plasmid DNA vaccines offer a significant improvement over conventional vaccine manufacturing technologies, the RapidResponse(TM) DNA vaccine platform could offer further advantages, especially in greater speed of production and lower cost. The company plans to continue development of its plasmid DNA vaccine programs because the technology is much closer to commercial realization in humans.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that coul
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)SALT LAKE CITY, Dec. 4 Dynatronics Corporation (Nasdaq: DYNT ) announced it has signed a sole-source vendor agreement to provide therapy equipment and rehab supplies to Benchmark Physical Therapy wi
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new d
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4ViroPharma Receives Complete Response Letter for Cinryze 28TM 29 Supplemental Biologics License Application for Acute Treatment of Hereditary Angioede 12463 1ViroPharma Receives Complete Response Letter for Cinryze 28TM 29 Supplemental Biologics License Application for Acute Treatment of Hereditary Angioede 12463 2ViroPharma Receives Complete Response Letter for Cinryze 28TM 29 Supplemental Biologics License Application for Acute Treatment of Hereditary Angioede 12463 3ViroPharma Receives Complete Response Letter for Cinryze 28TM 29 Supplemental Biologics License Application for Acute Treatment of Hereditary Angioede 12463 4ViroPharma Receives Complete Response Letter for Cinryze 28TM 29 Supplemental Biologics License Application for Acute Treatment of Hereditary Angioede 12463 5EUCODIS Bioscience Launches Beta Lactamase for Antibiotics and Diagnostics Industries 12462 1EUCODIS Bioscience Launches Beta Lactamase for Antibiotics and Diagnostics Industries 12462 2Cardiac Science to Present at Needham Biotechnology 26 Medical Technology Conference 47874 1Cardiac Science to Present at Needham Biotechnology 26 Medical Technology Conference 47874 2Cardiac Science to Present at Needham Biotechnology 26 Medical Technology Conference 47874 3
(Date:12/5/2009)--In Youngest Babies, This Type of Blood Cancer Is Most Challenging-- ,, PHILADELPHIA and NEW ORLEANS, Dec. 5 Pediatric oncologists have identified specific genes, dubbed partner genes, that fuse w
(Date:12/5/2009)Research debunks the ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- Pity the poor single people who pass their 40th birthday without ever tying the knot, s
(Date:12/5/2009)The MAMA campaign is a collaborative effort by the National Association of Certified Professional Midwives (NACPM), Midwives Alliance of North America (MANA), Citizens for Midwifery (CfM), Internation
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
Breaking Medicine News(10 mins):Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2
...s today filed an appeal in their challenge of a co...eld by the Wisconsin Alumni Research,Foundation (W... for Taxpayer and Consumer,Rights, and the Public ...s requested a re-examination of the patent,in July...
...nnipeg (July 18, 2008) Funding of $4.4 million fr...R) was announced today by Steven Fletcher, MP for ... Secretary for Health, on behalf of Tony Clement, ...Health Commission of Canada is contributing $250,0...
...chigan State University scholar refutes commonly h..., more emotionally unstable and harder to get alon...ith the findings, employers are urged to guard aga...ent, and two colleagues studied the relationship b...
...paign to raise awareness, of the importance of t... compliance rates across the United St...ation, a,nonprofit organization dedicated to healt...ay, July 19 in conjunction,with the Ebenezer Afric...
...eld,United Concordia Companies, Inc. and Catholic ...es and lifestyles for Pittsburghers. Beginning at ...y 19, a free clinic will,offer health information ...re than other aspects of health care. The percepti...
...t old drug offers new hope , , FRIDAY, Jul...ne step back in the search for treatments against ...e July 19 issue of The Lancet , an older drug cal...er,s -- even though it cleared dementia-linked amy...
Other Medicine News:Health News:Consumer Groups File Appeal on Challenge of Human Stem Cell Patent Held By WARF 2Health News:CIHR announces $4.4 million to improve mental health of Canadians 2Health News:Studies refute common stereotypes about obese workers 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 3Health News:Highmark Blue Cross Blue Shield, United Concordia and Catholic Charities Join Forces to Offer Free Health, Dental Services This Saturday 2Health News:Alzheimer's Research Brings Progress, Setbacks 2Health News:Alzheimer's Research Brings Progress, Setbacks 3Health News:Alzheimer's Research Brings Progress, Setbacks 4
49 Pinhole short handle
Frosted Long Handle Occluder
LM-380
LM 15C
Medicine Products: